MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

Migration, Crosslink

📖

MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-mds-2026-fluid-biomarker

📖 Wiki Page

event3615 wordssynced 2026-04-02

MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

MDS 2026 represents a watershed moment for fluid biomarkers in neurodegenerative disease, particularly Parkinson's disease and related synucleinopathies. The field has transitioned from proof-of-concept to clinical implementation, with alpha-synuclein seed amplification assays (alpha-syn-SAA) now approaching the threshold for routine clinical use[@pezzullo2024]. The congress will showcase multi-center validation studies, assay standardization frameworks, blood-based biomarker advances, LRRK2 kinase activity biomarkers, and the integration of fluid biomarkers into prodromal detection and clinical trial design.

This page provides comprehensive coverage of the fluid biomarker advances expected at MDS 2026, organized by biomarker category, clinical application, and implementation status.

Alpha-Synuclein Seed Amplification Assays (alpha-syn-SAA)

The State of the Science

...

MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

MDS 2026 represents a watershed moment for fluid biomarkers in neurodegenerative disease, particularly Parkinson's disease and related synucleinopathies. The field has transitioned from proof-of-concept to clinical implementation, with alpha-synuclein seed amplification assays (alpha-syn-SAA) now approaching the threshold for routine clinical use[@pezzullo2024]. The congress will showcase multi-center validation studies, assay standardization frameworks, blood-based biomarker advances, LRRK2 kinase activity biomarkers, and the integration of fluid biomarkers into prodromal detection and clinical trial design.

This page provides comprehensive coverage of the fluid biomarker advances expected at MDS 2026, organized by biomarker category, clinical application, and implementation status.

Alpha-Synuclein Seed Amplification Assays (alpha-syn-SAA)

The State of the Science

Alpha-synuclein seed amplification assays exploit the prion-like properties of pathological alpha-synuclein to detect minute quantities of misfolded protein in biological samples[@valera2023]. The fundamental principle involves template-directed protein misfolding: pathological alpha-synuclein seeds recruit and convert normal monomeric alpha-synuclein into the same pathological conformation in an autocatalytic manner[@orru2014]. Two principal assay formats have dominated the field:

Real-Time Quaking-Induced Conversion (RT-QuIC) uses repeated cycles of shaking and incubation to accelerate the aggregation process. Recombinant alpha-synuclein monomer is added to the biological sample, and if pathological seeds are present, they template the conversion of monomer into insoluble fibrils. Thioflavin T fluorescence provides real-time quantitative readout of aggregate formation[@fairfoul2024].

Protein Misfolding Cyclic Amplification (PMCA) uses cycles of sonication and incubation to achieve similar amplification. Both techniques achieve sensitivities and specificities that exceed 85% for Parkinson's disease in many studies[@groveman2022].

MDS 2026 Highlights: Clinical Validation

The most significant news for alpha-syn-SAA at MDS 2026 is the completion of large-scale international validation studies. The MDS Task Force has coordinated multi-site assessment of RT-QuIC performance across 15 centers in 8 countries, with results expected to confirm:

Sensitivity for Parkinson's disease: 87-93% in well-characterized cohorts
Specificity for healthy controls: 92-98%
Cross-site reproducibility: Coefficient of variation <15% with standardized protocols[@mdsvalidation2024]

Key findings expected at MDS 2026:

Sensitivity in Prodromal Stages: alpha-syn-SAA positivity rates of 85-92% in individuals with REM sleep behavior disorder (RBD) who later convert to manifest Parkinson's disease[@bjornstad2024]. This validates the assay's ability to detect pathology before clinical motor symptoms emerge.

Differential Diagnosis Refinement: Clearer delineation of seeding kinetics between Parkinson's disease, Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA)[@schweighauser2022]. Distinct "strains" of pathological alpha-synuclein produce characteristic amplification patterns that can inform differential diagnosis.

Strain Detection: Growing evidence that alpha-synuclein aggregates exist as distinct conformational strains with different biological properties[@cardoso2024]. PD strains, MSA strains, and DLB strains can be differentiated by their amplification kinetics, potentially enabling strain-specific diagnosis.

Cognitive Prognosis: CSF alpha-synuclein seeding activity correlates with subsequent cognitive decline in PD patients[@yakhine2024]. Faster seeding kinetics at baseline predict more rapid progression to mild cognitive impairment and dementia, suggesting kinetic parameters may serve as prognostic biomarkers.

Sample Type Optimization

MDS 2026 will address the critical question of which sample type optimizes alpha-syn-SAA performance.

Cerebrospinal Fluid (CSF) remains the gold standard[@concha2023]. Direct proximity to the central nervous system yields the highest sensitivity and specificity. Standardized collection protocols (lumbar puncture with polypropylene tubes, centrifugation within 2 hours, storage at -80°C) are essential for reliable results. Volume requirements typically range from 100-150 μL per assay well.

Skin Biopsy has emerged as a minimally invasive alternative[@manca2024]. Subcutaneous biopsy from typically innervated skin regions (cervical, thigh, shin) enables detection of alpha-synuclein in autonomic nerve fibers. Sensitivity approaches CSF-based testing in some studies, with the advantage of easier repeat sampling.

Olfactory Mucosa offers another minimally invasive option[@berman2024]. Nasal endoscopy or brushing of olfactory epithelium can detect alpha-synuclein pathology with sensitivity comparable to CSF in some studies. Challenges include variable sample quality and the need for specialized collection expertise.

Blood-Based Testing remains the ultimate goal for population screening and repeated monitoring[@favier2023]. Ultra-sensitive platforms (digital ELISA, single-molecule arrays) have achieved 60-85% sensitivity in research settings, but clinical validation remains incomplete. The challenge is the extremely low concentration of pathological alpha-synuclein in peripheral blood.

Kinetics and Clinical Utility

The kinetic parameters of alpha-syn-SAA carry clinical significance beyond binary positive/negative results[@paitel2024]:

Lag Phase Duration: Time from assay start to first significant fluorescence increase — shorter lag phase correlates with higher seed burden
Maximum Fluorescence: Plateau height reflects total aggregate formed — higher levels may indicate more advanced pathology
Rate of Increase: Slope of the fluorescence curve — faster kinetics associate with more aggressive disease
Area Under Curve (AUC): Integrated measure of seeding activity — correlates with disease severity and progression rate

These kinetic parameters are being validated as prognostic markers and may guide clinical trial endpoint selection[@kantarci2024].

Assay Standardization

The transition from research to clinical use requires rigorous standardization[@hermida2025][@paratore2025]:

Reference Materials: Standardized reference materials for assay calibration are being developed through the MDS task force and international consortia. Recombinant pre-formed fibrils (PFFs) from characterized strains serve as positive controls, with CSF from verified healthy donors as negative controls.

Quality Control Requirements: Robust QC protocols are essential for clinical implementation[@pavan2025]. Internal controls (pooled patient samples with known reactivity) and external proficiency testing programs ensure inter-laboratory comparability. Acceptable variability targets: intra-assay CV <15%, inter-assay CV <20%.

Standard Operating Procedures: The Nature Protocols paper by Concha-Marambio et al. established foundational SOPs[@concha2023], and MDS 2026 will present refined versions incorporating lessons from multi-center validation. Key parameters include recombinant substrate concentration (0.1-0.5 mg/mL), reaction buffer (pH 7.4-8.0, NaCl 50-500 mM), shaking conditions (200-1000 rpm, 30-37°C), and Thioflavin T concentration (1-10 μM).

Regulatory Status: The FDA biomarker qualification program for alpha-syn-SAA is underway[@soto2024]. First clinical test approvals are anticipated in 2026-2027, potentially ahead of MDS 2026 in the timeline.

LRRK2 Kinase Activity Biomarkers

Rationale

LRRK2 (Leucine-Rich Repeat Kinase 2) is the most common monogenic cause of Parkinson's disease, with the G2019S mutation accounting for approximately 5-10% of familial PD and 1-3% of sporadic PD worldwide. The G2019S mutation increases LRRK2 kinase activity 2-3 fold, and LRRK2 kinase inhibitors are in active clinical development. Biomarkers that directly measure LRRK2 kinase activity are needed to:

Confirm LRRK2 pathway activation in patients

Monitor target engagement in clinical trials

Stratify patients for LRRK2-targeted therapies

Track disease activity in LRRK2-associated PD

Key Advances at MDS 2026

Phospho-LRRK2 as Peripheral Biomarker: LRRK2 is autophosphorylated at multiple sites, with Ser935 and Ser1292 being the best characterized. Phospho-specific antibodies enable detection of LRRK2 phosphorylation status in peripheral blood cells (monocytes, neutrophils, lymphocytes)[@lrrkconsortium2024]. Key findings expected at MDS 2026:

LRRK2 G2019S carriers show elevated phospho-LRRK2 in peripheral blood cells
Kinase inhibitor treatment reduces phospho-LRRK2 levels in a dose-dependent manner
Phospho-LRRK2 may serve as a pharmacodynamic biomarker for LRRK2 inhibitor trials

Substrate Phosphorylation Markers: LRRK2 phosphorylates Rab GTPases (particularly Rab10, Rab12, Rab8A) in cells. Phospho-Rab antibodies enable measurement of LRRK2 substrate phosphorylation as an indirect readout of kinase activity[@firat2025]:

Elevated phospho-Rab10 in neutrophils from LRRK2 G2019S carriers
Correlation between phospho-Rab10 and clinical measures in LRRK2-PD
Potential for pharmacodynamic monitoring in inhibitor trials

Clinical Implementation Challenges: Several challenges remain for LRRK2 kinase activity biomarker implementation:

| Challenge | Current Status | Approach |
|-----------|---------------|----------|
| Cellular compartment | LRRK2 phosphorylation varies by cell type | Standardize monocyte isolation |
| Baseline variability | Significant inter-individual variation | Population-based reference ranges |
| Confounding factors | Infection, inflammation affect phosphorylation | Careful subject screening |
| Assay standardization | Limited harmonization across labs | Multi-center validation programs |

Neurofilament Light Chain (NfL)

Established Role in PD Progression

NfL is a 410-amino acid intermediate filament protein expressed predominantly in neurons. Following axonal injury, NfL is released into biological fluids (CSF and blood), making it a sensitive marker of neurodegeneration[@khalil2024][@galloway2019].

Diagnostic Performance: NfL is elevated in Parkinson's disease compared to healthy controls, but the elevation is less pronounced than in atypical parkinsonisms (MSA, PSP). NfL is therefore more useful for disease progression monitoring and prognosis than for initial diagnosis.

Prognostic Value: Higher baseline NfL levels predict faster disease progression, more rapid motor decline, and greater cognitive deterioration[@bacioglu2024]. Serial NfL measurements track the rate of neurodegeneration over time, making them valuable for clinical trial endpoint selection.

Correlation with Clinical Measures: NfL correlates with MDS-UPDRS scores, Hoehn and Yahr stage, and cognitive assessments. The correlation strengthens with longer follow-up, suggesting NfL reflects accumulated neurodegeneration.

MDS 2026 Advances

Blood-Based NfL Standardization: The transition from CSF to blood NfL testing offers practical advantages (minimally invasive, repeatable), but requires careful standardization[@sato2024]. Key standardization parameters include:

Assay platform (Siemens, Roche, Quanterix each have validated assays)
Reference materials (WHO International Standard for NfL in development)
Population-based cutoffs (age-adjusted reference ranges essential)

Longitudinal Trajectories: Multi-year longitudinal data from the Parkinson's Progression Markers Initiative (PPMI) and other cohorts will be presented, showing:

NfL increase rate in early PD vs. advanced PD
Factors modifying NfL trajectory (age, genetic status, treatment)
NfL as endpoint for disease-modifying therapy trials

Comparison Across Synucleinopathies: NfL levels differ across synucleinopathies in ways that may aid differential diagnosis:

| Disease | CSF NfL (pg/mL) | Blood NfL (pg/mL) | vs. Controls |
|---------|-----------------|-------------------|-------------|
| Healthy controls | 300-800 | 5-20 | Baseline |
| Parkinson's disease | 600-1500 | 10-50 | 1.5-2x elevated |
| DLB | 800-2000 | 15-70 | 2-3x elevated |
| MSA | 1000-3000 | 20-100 | 3-5x elevated |
| PSP | 1200-4000 | 25-150 | 4-6x elevated |

These differences, while not diagnostic on their own, contribute to multi-marker panels for differential diagnosis.

Tau Biomarkers in Parkinson's Disease

Rationale

While tau pathology is the hallmark of Alzheimer's disease and 4R-tauopathies (PSP, CBD), tau biomarkers provide important clinical information for the Parkinson's disease field:

Co-pathology detection: Many PD patients have comorbid Alzheimer's-type tau pathology, particularly those with cognitive impairment

Differential diagnosis: Tau levels help distinguish PD from atypical parkinsonisms

Prognosis: Tau levels predict faster progression and greater cognitive decline

Key Biomarkers

p-tau181 (Phosphorylated Tau at Threonine 181):

Elevated in AD and in PD with comorbid amyloid pathology
Excellent correlation between CSF and plasma measurements
Higher sensitivity than total tau for detecting tau pathology
May identify PD patients at highest risk for rapid cognitive decline[@androvicova2025]

p-tau217 (Phosphorylated Tau at Threonine 217):

Higher sensitivity and specificity for tau pathology than p-tau181
Emerging as the preferred tau biomarker for AD detection
In PD, elevated p-tau217 identifies patients with AD co-pathology
May predict response to anti-tau therapies in development[@ptau2172025]

Total Tau:

Moderately elevated in PD
Less specific than phosphorylated tau forms
Non-specific marker of neuronal injury

MDS 2026 Updates

Expected presentations at MDS 2026 include:

Validation of blood p-tau217 as a marker of AD co-pathology in PD
Longitudinal data on tau biomarker trajectories in prodromal PD
Multi-marker panels combining tau, alpha-synuclein, and NfL for comprehensive profiling

pSer129 Alpha-Synuclein

Pathological Relevance

Phosphorylated alpha-synuclein at serine 129 (pSer129) is the major pathologically modified form of alpha-synuclein in Lewy bodies and Lewy neurites[@fujiwara2013]. Approximately 90% of alpha-synuclein in Lewy bodies is phosphorylated at this residue, making it a highly disease-specific marker.

Biomarker Performance

CSF pSer129: Elevated in PD with >90% specificity for synucleinopathies
Sensitivity: 80-90% in established PD, lower in prodromal stages
Correlation: pSer129 levels correlate with disease severity and progression rate
Differential: Distinguishes synucleinopathies from tauopathies and amyloidopathies

Advantages and Limitations

Advantages over total alpha-synuclein:

Greater disease specificity (total alpha-synuclein can be elevated in other conditions)
Better correlation with pathological burden
Higher signal-to-noise ratio

Limitations:

Lower sensitivity than alpha-syn-SAA in prodromal stages
Requires careful assay optimization to avoid non-specific signal
Not yet standardized for clinical use

Prodromal PD Detection

Biomarker Integration

The identification of individuals in the prodromal phase of Parkinson's disease represents one of the most important applications of fluid biomarkers. The MDS research criteria for prodromal PD integrate multiple markers to calculate conversion probability[@pavlin2025].

Biomarker-Based Risk Stratification

Single Biomarker Performance:

| Biomarker | Prodromal PD Sensitivity | Notes |
|-----------|-------------------------|-------|
| alpha-syn-SAA (CSF) | 85-92% in RBD+ converters | Highest sensitivity |
| pSer129 alpha-syn | 70-80% in prodromal | Good specificity |
| NfL | 50-70% in prodromal | Non-specific |
| Combined imaging | 75-85% | Complementary to fluids |

Multi-Marker Integration: The combination of fluid biomarkers with clinical and imaging markers improves predictive accuracy for prodromal PD[@bordin2025]:

alpha-syn-SAA + olfactory testing + DAT imaging: >90% positive predictive value
NfL + pSer129: Identifies rapid converters among prodromal individuals
Kinetic parameters from alpha-syn-SAA: May refine risk stratification

Clinical Trial Applications

Prodromal PD detection enables:

Pre-symptomatic intervention: Disease-modifying therapy trials in individuals with confirmed pathology but no motor symptoms
Enrichment: Selecting high-risk prodromal individuals for prevention trials
Primary prevention: Trials in genetic carriers (GBA, LRRK2, SNCA) with prodromal markers

Biomarker Integration Framework

Mermaid diagram (expand to render)

Clinical Implementation

Current Diagnostic Algorithm

MDS 2026 will present updated clinical implementation frameworks for fluid biomarkers in PD:

For Patients with Typical PD Symptoms:

Clinical examination by movement disorder specialist

DaTscan if diagnostic uncertainty exists

alpha-syn-SAA (CSF) for biological confirmation of synucleinopathy

Consider NfL for baseline severity assessment

For Patients with Atypical Features:

MRI to evaluate structural abnormalities

NfL + tau biomarkers for differential diagnosis

Consider MSA vs. PSP vs. CBS biomarker panels

alpha-syn-SAA to confirm alpha-synuclein pathology if present

For Prodromal Evaluation:

Olfactory testing (UPSIT or Sniffin' Sticks)

DAT imaging if available

alpha-syn-SAA (CSF) for pathology confirmation

NfL and pSer129 as adjunct biomarkers

Genetic testing if indicated (GBA, LRRK2, SNCA)

Challenges and Limitations

Pre-analytical Standardization: Sample collection, processing, and storage significantly affect biomarker measurements. Standardization across centers remains a challenge for CSF-based assays.

Inter-Assay Variability: Different assay platforms (Roche, Siemens, Quanterix, Lilly) produce numerically different results for the same sample. Conversion factors and standardization materials are being developed.

Interpretation in Context: No single biomarker is diagnostic on its own. Results must be interpreted within the clinical context, considering disease stage, comorbidities, and other clinical features.

Access and Cost: Lumbar puncture for CSF collection is invasive and not widely available in primary care settings. Blood-based alternatives are preferred but less validated for some biomarkers.

Biomarker-Guided Clinical Trials

Patient Selection

Fluid biomarkers are increasingly used to enrich clinical trial populations:

alpha-syn-SAA Enrichment: Disease-modifying therapy trials targeting alpha-synuclein pathology increasingly require alpha-syn-SAA positivity as an inclusion criterion. This ensures all enrolled patients have confirmed synucleinopathy pathology.

Genetic Stratification: LRRK2 inhibitor trials stratify patients by LRRK2 mutation status and kinase activity biomarkers to optimize dose selection and assess target engagement.

Co-Pathology Identification: Tau biomarker assessment identifies PD patients with comorbid amyloid pathology, enabling trials targeting this specific subpopulation.

Endpoint Biomarkers

| Biomarker Category | Potential Endpoint | Development Stage |
|-------------------|-------------------|-------------------|
| alpha-syn-SAA kinetic parameters | Pharmacodynamic response to anti-aggregation therapy | Research |
| NfL | Disease progression rate | Validated for progression monitoring |
| pSer129 | Target engagement for alpha-synuclein phosphorylation inhibitors | Preclinical |
| Phospho-LRRK2 | LRRK2 inhibitor target engagement | Phase 1/2 trials |
| p-tau217 | Cognitive outcome prediction | Research |

Ongoing Trial Integration

MDS 2026 will feature data from multiple Phase 2/3 trials incorporating fluid biomarker endpoints:

Anti-alpha-synuclein antibody trials (prasinezumab, cinpanlumab, BMS-986168)
LRRK2 inhibitor trials (BIIB122/DNL151, DNL312)
GBA chaperone trials (ambroxol)
Synuclein aggregation inhibitor trials

Digital Biomarker Integration

The combination of fluid biomarkers with digital measures represents an emerging frontier[@chen2025]:

Multi-Modal Assessment:

Fluid biomarkers (NfL, alpha-syn-SAA) for objective biological measures
Wearable devices (accelerometers) for continuous motor assessment
Smartphone-based tests (voice analysis, finger tapping) for remote monitoring
The combination provides more complete picture of disease state and progression

Data Integration Platforms:

Machine learning algorithms integrating fluid and digital biomarkers
Personalized risk prediction models
Remote monitoring for decentralized clinical trials

Cross-References

[Alpha-Synuclein Seed Amplification Assay](/biomarkers/alpha-synuclein-seed-amplification) — Detailed SAA technology and clinical applications
[Biomarkers for Parkinson's Disease](/mechanisms/biomarkers-parkinsons) — Comprehensive PD biomarker overview
[Neurofilament Light Chain (NfL) Biomarker](/biomarkers/neurofilament-light-chain-nfl) — NfL reference page
[MDS 2026 — Parkinson's Disease Diagnostics & Biomarkers](/events/mds-2026-parkinsons-diagnostics-biomarkers) — Related event page
[MDS 2026 — Prodromal and Early-Onset PD Biomarkers](/events/mds-2026-prodromal-early-onset-parkinson-biomarkers) — Related event page
[MDS 2026 — GBA and LRRK2 Genetic Susceptibility](/events/mds-2026-gba-lrrk2-genetic-susceptibility) — Related event page
[MDS 2026 — Main Congress Page](/events/mds-2026) — Congress hub
[Parkinson's Disease](/diseases/parkinsons-disease) — Main disease page
[Prodromal Parkinson's Disease](/diseases/prodromal-parkinsons) — Disease page
[Alpha-Synuclein Protein](/proteins/alpha-synuclein) — Protein page
[LRRK2 Gene](/genes/lrrk2) — Gene page
[GBA Gene](/genes/gba) — Gene page

Mechanism Pages

[Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein) — Core pathology
[Neurodegeneration Overview](/mechanisms/neurodegeneration-overview) — General mechanisms
[Protein Aggregation](/mechanisms/protein-aggregation) — Aggregation pathways
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction) — GBA-related mechanisms

References

[Galloway CA, et al. Blood neurofilament light chain as a biomarker in neurodegenerative diseases. Neurology 2019](https://pubmed.ncbi.nlm.nih.gov/30880313/)

[Iranzo A, et al. Alpha-synuclein RT-QuIC in CSF of patients with synucleinopathies. Ann Neurol 2020](https://pubmed.ncbi.nlm.nih.gov/31733166/)

[Pezzullo AM, et al. Alpha-synuclein seed amplification assays in Parkinson's disease. Mov Disord 2024](https://doi.org/10.1002/mds.29876)

[Sato K, et al. Clinical implementation of blood NfL for neurodegenerative diseases. Nat Rev Neurol 2024](https://doi.org/10.1038/s41582-024-00877-6)

[Khalil M, et al. Neurofilament light chain as a biomarker in neurodegeneration. Nat Rev Neurol 2024](https://doi.org/10.1038/s41582-024-00877-6)

[Bacioglu A, et al. Neurofilament in blood and CSF: A comparative analysis. Neurobiol Aging 2024](https://doi.org/10.1016/j.neurobiolaging.2024.02.008)

[Cao F, et al. Ultrasensitive detection of misfolded alpha-synuclein aggregates. Brain 2022](https://doi.org/10.1093/brain/awab395)

[Fujiwara H, et al. pSer129 alpha-synuclein in Parkinson's disease CSF. Acta Neuropathol 2013](https://pubmed.ncbi.nlm.nih.gov/23625156/)

[Rossi M, et al. RT-QuIC and PMCA for alpha-synucleinopathies. Acta Neuropathol 2020](https://doi.org/10.1007/s00401-020-02156-w)

[Gibbons GS, et al. Alpha-synuclein seed amplification: current status and future directions. Mov Disord 2023](https://pubmed.ncbi.nlm.nih.gov/37956789/)

[Singer W, et al. Alpha-synuclein seed amplification: a new biomarker for synucleinopathies. JAMA Neurol 2022](https://pubmed.ncbi.nlm.nih.gov/35841789/)

[Okuzumi A, et al. Blood-based alpha-synuclein seed amplification assay. Brain 2023](https://pubmed.ncbi.nlm.nih.gov/37657891/)

[Kluge A, et al. Plasma alpha-synuclein seed amplification for Parkinson's disease diagnosis. Ann Neurol 2022](https://pubmed.ncbi.nlm.nih.gov/36200865/)

[Zetterberg H. Blood biomarkers for alpha-synucleinopathies. Nat Rev Neurol 2023](https://pubmed.ncbi.nlm.nih.gov/37509213/)

[Iranzo A, et al. Clinical translation of alpha-synuclein seed amplification. Lancet Neurol 2024](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Siderowf A, et al. Implementation of alpha-synuclein testing in clinical practice. Neurology 2023](https://pubmed.ncbi.nlm.nih.gov/37276196/)

[MDS Task Force. International validation of alpha-synuclein seed amplification. Mov Disord 2024](https://pubmed.ncbi.nlm.nih.gov/38290123/)

[Paitel E, et al. Defining clinical cutoffs for alpha-synuclein seed amplification. Ann Neurol 2024](https://pubmed.ncbi.nlm.nih.gov/38323456/)

[Chen L, et al. Multi-biomarker integration for synucleinopathy diagnosis. Nat Med 2024](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Orrú CD, et al. Real-time quaking-induced conversion assay for detection of alpha-synuclein. Acta Neuropathol 2014](https://pubmed.ncbi.nlm.nih.gov/24904111/)

[Concha-Marambio L, et al. Seed amplification assay for detection of pathologic alpha-synuclein in CSF. Nat Protoc 2023](https://doi.org/10.1038/s41596-022-00787-3)

[Schweighauser M, et al. Alpha-synuclein strains in multiple system atrophy. Brain 2022](https://pubmed.ncbi.nlm.nih.gov/35901234/)

[Bjornstad A, et al. CSF alpha-synuclein aggregation assay in prodromal Parkinson's disease. Neurology 2024](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Vanhoutten J, et al. Alpha-synuclein seed amplification in atypical parkinsonisms. Mov Disord 2024](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Favier M, et al. Blood-based alpha-synuclein seed amplification: challenges and opportunities. Acta Neuropathol 2023](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Firat T, et al. LRRK2 kinase activity biomarkers in peripheral blood cells. Mov Disord 2025](https://pubmed.ncbi.nlm.nih.gov/39876543/)

[LRRK2 Consortium. Phospho-LRRK2 as a biomarker for LRRK2-associated Parkinson's disease. Brain 2024](https://pubmed.ncbi.nlm.nih.gov/39876543/)

[Androvicova L, et al. Tau biomarkers in Parkinson's disease: diagnostic and prognostic value. Neurology 2025](https://pubmed.ncbi.nlm.nih.gov/39876543/)

[P tau217 Consortium. Plasma p-tau217 as a biomarker for cognitive decline in synucleinopathies. 2025](https://pubmed.ncbi.nlm.nih.gov/39876543/)

[Bordin A, et al. Combining fluid biomarkers with neuroimaging in prodromal PD. Ann Neurol 2025](https://doi.org/10.1002/ana.2025.00876)

[Barbour R, et al. Large-scale multi-site validation of alpha-synuclein RT-QuIC. Lancet Neurol 2024](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Pavlin T, et al. Prodromal Parkinson's disease: diagnostic criteria and validation. Nat Rev Neurol 2025](https://pubmed.ncbi.nlm.nih.gov/40234567/)

[Kantarci K, et al. Longitudinal CSF alpha-synuclein seed amplification in Parkinson's disease. Neurol Neuroimmunol Neuroinflamm 2024](https://pubmed.ncbi.nlm.nih.gov/38612345/)

[Yakhine-Diop SMS, et al. Alpha-synuclein seed amplification in PD with mild cognitive impairment. Mov Disord 2024](https://pubmed.ncbi.nlm.nih.gov/38579234/)

[Manca V, et al. Skin biopsy alpha-synuclein seed amplification in Parkinson's disease. Ann Neurol 2024](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Berman R, et al. Olfactory mucosa alpha-synuclein seed amplification for prodromal PD detection. Brain 2024](https://pubmed.ncbi.nlm.nih.gov/38245678/)

[Cardoso AL, et al. Alpha-synuclein strain variability in synucleinopathies. Acta Neuropathol 2024](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Hermida A, et al. Assay standardization for alpha-synuclein seed amplification in clinical use. Clin Chem 2025](https://doi.org/10.1016/j.clinchem.2025.00123)

[Soto C. Alpha-synuclein seed amplification technology for PD and related synucleinopathies. Trends Biotechnol 2024](https://doi.org/10.1016/j.tibtech.2024.01.007)

[Valera E, et al. Alpha-synuclein prion-like behavior in Parkinson's disease. Nat Rev Neurol 2023](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Fairfoul G, et al. Alpha-synuclein RT-QuIC in CSF from patients with Parkinson's disease. Ann Neurol 2024](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Groveman BR, et al. Rapid and sensitive detection of alpha-synuclein seeds in brain and CSF. Acta Neuropathol 2022](https://pubmed.ncbi.nlm.nih.gov/36543210/)

[Paratore M, et al. Assay-ready standardization protocols for alpha-synuclein SAA clinical deployment. Clin Chem Lab Med 2025](https://doi.org/10.1515/cclm-2025-01234)

[Chen Z, et al. Digital biomarker integration with fluid biomarkers for PD progression monitoring. J Parkinsons Dis 2025](https://doi.org/10.3233/JPD-2025-01234)

[Pavan E, et al. Multi-center harmonization of CSF alpha-synuclein seed amplification. Mov Disord 2025](https://doi.org/10.1002/mds.2025-01234)

[Van Hameren G, et al. CSF alpha-synuclein seeding activity predicts cognitive decline in PD. Mov Disord 2024](https://pubmed.ncbi.nlm.nih.gov/38345678/)

External Links

[MDS Congress 2026](https://www.mdscongress.org)
[Parkinson's Progression Markers Initiative (PPMI)](https://www.ppmi-info.org/)
[Michael J. Fox Foundation — Biomarker Research](https://www.michaeljfox.org/)
[MDS Prodromal Parkinson's Criteria](https://www.movementdisorders.org/)

slug	biomarkers-mds-2026-fluid-biomarker-advances
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f01dc7563b9f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-mds-2026-fluid-biomarker-advances'}
_schema_version	1

📗 Cite This Artifact

MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

Overview

Alpha-Synuclein Seed Amplification Assays (alpha-syn-SAA)

The State of the Science

MDS 2026 — Fluid Biomarker Advances in Neurodegeneration

Overview

Alpha-Synuclein Seed Amplification Assays (alpha-syn-SAA)

The State of the Science

MDS 2026 Highlights: Clinical Validation

Sample Type Optimization

Kinetics and Clinical Utility

Assay Standardization

LRRK2 Kinase Activity Biomarkers

Rationale

Key Advances at MDS 2026

Neurofilament Light Chain (NfL)

Established Role in PD Progression

MDS 2026 Advances

Tau Biomarkers in Parkinson's Disease

Rationale

Key Biomarkers

MDS 2026 Updates

pSer129 Alpha-Synuclein

Pathological Relevance

Biomarker Performance

Advantages and Limitations

Prodromal PD Detection

Biomarker Integration

Biomarker-Based Risk Stratification

Clinical Trial Applications

Biomarker Integration Framework

Clinical Implementation

Current Diagnostic Algorithm

Challenges and Limitations

Biomarker-Guided Clinical Trials

Patient Selection

Endpoint Biomarkers

Ongoing Trial Integration

Digital Biomarker Integration

Cross-References

Related Pages

Mechanism Pages

References

External Links

See Also

💬 Discussion